Esperoct is indicated for the treatment of hemophilia A in adults and children [1].
What is Hemophilia A?
Hemophilia A is a genetic bleeding disorder characterized by a deficiency in clotting factor VIII. Without sufficient functional factor VIII, blood does not clot properly, leading to prolonged bleeding after injuries or surgery, and spontaneous bleeding into joints and muscles [1][2].
How does Esperoct work?
Esperoct is a recombinant factor VIII (rFVIII) concentrate. It replaces or supplements the deficient clotting factor VIII in individuals with hemophilia A, thereby enabling the blood to clot and preventing or controlling bleeding episodes [1].
What are the benefits of using Esperoct?
Esperoct is designed for prophylactic treatment, meaning it is used regularly to prevent bleeding. Its longer half-life compared to some other factor VIII treatments may allow for less frequent infusions, potentially improving convenience for patients [1][3].
When does Esperoct patent exclusivity expire?
Information on specific patent expiry dates for Esperoct is proprietary and not publicly disclosed in the provided material. For detailed patent information, resources like DrugPatentWatch.com can be consulted [4].
Who manufactures Esperoct?
Esperoct is manufactured by Novo Nordisk [1].
What clinical data supports Esperoct's use?
Clinical trials have evaluated Esperoct's safety and efficacy in treating hemophilia A. Studies have demonstrated its ability to reduce annualized bleeding rates in patients receiving prophylactic treatment [1][3].